The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
Abstract
The first clinical trial of an MF59(®)-adjuvanted influenza vaccine (Novartis) was conducted 20 years ago in 1992. The product that emerged (Fluad(®), Novartis) was licensed first in Italy in 1997 and is now licensed worldwide in 30 countries. US licensure is expected in the coming years. By contrast, many alternative adjuvanted vaccines have failed to progress. The key decisions that allowed MF59 to succeed in such a challenging environment are highlighted here and the lessons that were learned along the way are discussed. MF59 was connected to vaccines that did not succeed and was perceived as a 'failure' before it was a success. Importantly, it never failed for safety reasons and was always well tolerated. Even when safety issues have emerged for alternative adjuvants, careful analysis of the substantial safety database for MF59 have shown that there are no significant concerns with widespread use, even in more 'sensitive' populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213
Effectiveness of maternal influenza immunization in mothers and infants
Zaman, K., Roy, E., Arifeen, S. E., Rahman, M., Raqib, R., Wilson, E., Omer, S. B., Shahid, N. S., Breiman, R. F., & Steinhoff, M. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708630 · Cited by 1,227
Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives
Ellouz, F., Adam, A., Ciorbaru, R., & Lederer, E. (1974) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(74)90458-6 · Cited by 1,019
Hobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,002
Wilkinson, T. M., Li, C. K. F., Chui, C. S. C., Huang, A. K. Y., Perkins, M., Liebner, J. C., Lambkin-Williams, R., Gilbert, A., Oxford, J., Nicholas, B., et al. (2012) · Nature Medicine · doi:10.1038/nm.2612 · Cited by 974
Nod-like proteins in immunity, inflammation and disease
Fritz, J. H., Ferrero, R. L., Philpott, D. J., & Girardin, S. E. (2006) · Nature Immunology · doi:10.1038/ni1412 · Cited by 892
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G., & Hall, B. D. (1982) · Nature · doi:10.1038/298347a0 · Cited by 877
Wrammert, J., Koutsonanos, D., Li, G.-M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M., Skountzou, I., Hornig, M., Lipkin, W. I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101352 · Cited by 777
Vaccine Prevention of Maternal Cytomegalovirus Infection
Pass, R. F., Zhang, C., Evans, A., Simpson, T., Andrews, W., Huang, M.-L., Corey, L., Hill, J., Davis, E., Flanigan, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804749 · Cited by 713
Influenza vaccine: The challenge of antigenic drift
CARRAT, F., & FLAHAULT, A. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.07.027 · Cited by 708
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055778 · Cited by 698
(1992) · International Journal of Biochemistry · doi:10.1016/0020-711x(92)90281-5 · Cited by 671
Vaccines for preventing influenza in healthy children
Jefferson, T., Rivetti, A., Di Pietrantonj, C., Demicheli, V., & Ferroni, E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004879.pub4 · Cited by 553
Nohynek, H., Jokinen, J., Partinen, M., Vaarala, O., Kirjavainen, T., Sundman, J., Himanen, S.-L., Hublin, C., Julkunen, I., Olsén, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033536 · Cited by 498
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
Self-citationResponse to a Monovalent 2009 Influenza A (H1N1) Vaccine
Greenberg, M. E., Lai, M. H., Hartel, G. F., Wichems, C. H., Gittleson, C., Bennet, J., Dawson, G., Hu, W., Leggio, C., Washington, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907413 · Cited by 492
Corey, L., Langenberg, A. G. M., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, Jr., Handsfield, H. H., Warren, T., Marr, L., Tyring, S., et al. (1999) · JAMA · doi:10.1001/jama.282.4.331 · Cited by 490
The mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
Self-citationMorel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., & Carlsen, H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.011 · Cited by 476
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
Clark, T. W., Pareek, M., Hoschler, K., Dillon, H., Nicholson, K. G., Groth, N., & Stephenson, I. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907650 · Cited by 445
Nicholson, K. G., Colegate, A. E., Podda, A., Stephenson, I., Wood, J., Ypma, E., & Zambon, M. C. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05066-2 · Cited by 440
Calabro, S., Tortoli, M., Baudner, B. C., Pacitto, A., Cortese, M., O’Hagan, D. T., De Gregorio, E., Seubert, A., & Wack, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.090 · Cited by 433
Self-citationSeubert, A., Monaci, E., Pizza, M., O’Hagan, D. T., & Wack, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5402 · Cited by 430
Self-citationPartinen, M., Saarenpää-Heikkilä, O., Ilveskoski, I., Hublin, C., Linna, M., Olsén, P., Nokelainen, P., Alén, R., Wallden, T., Espo, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033723 · Cited by 406
Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K., Castellino, F., Lattanzi, M., Del Giudice, G., Rappuoli, R., & Golding, H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002336 · Cited by 356
Self-citationBlack, S., Nicolay, U., Vesikari, T., Knuf, M., Del Giudice, G., Della Cioppa, G., Tsai, T., Clemens, R., & Rappuoli, R. (2011) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3182367662 · Cited by 334
Self-citation2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature
Mosby, L. G., Rasmussen, S. A., & Jamieson, D. J. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.12.033 · Cited by 334
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
Allison, A. C., & Byars, N. E. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90402-3 · Cited by 315
Sensitization and Antibody Formation after Injection of Tubercle Bacilli and Paraffin Oil.
Freund, J., Casals, J., & Hosmer, E. P. (1937) · Experimental Biology and Medicine · doi:10.3181/00379727-37-9625 · Cited by 311
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., & Ganne, V (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.111 · Cited by 308
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
Self-citationStephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 285
O’Hagan, D. T. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.699 · Cited by 282
Self-citationThe path to a successful vaccine adjuvant – ‘The long and winding road’
O’Hagan, D. T., & De Gregorio, E. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.009 · Cited by 274
Self-citationKhurana, S., Chearwae, W., Castellino, F., Manischewitz, J., King, L. R., Honorkiewicz, A., Rock, M. T., Edwards, K. M., Del Giudice, G., Rappuoli, R., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000624 · Cited by 268
Self-citationGalli, G., Hancock, K., Hoschler, K., DeVos, J., Praus, M., Bardelli, M., Malzone, C., Castellino, F., Gentile, C., McNally, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903181106 · Cited by 263
Galli, G., Medini, D., Borgogni, E., Zedda, L., Bardelli, M., Malzone, C., Nuti, S., Tavarini, S., Sammicheli, C., Hilbert, A. K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813390106 · Cited by 261
Self-citationEdelman, R. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.3.370 · Cited by 245
de Jong, J. C., Beyer, W. E. P., Palache, A. M., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2000) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(200005)61:1<94::aid-jmv15>3.0.co;2-c · Cited by 230
Schultze, V., D’Agosto, V., Wack, A., Novicki, D., Zorn, J., & Hennig, R. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.093 · Cited by 227
Influence of Prior Influenza Vaccination on Antibody and B-Cell Responses
Sasaki, S., He, X.-S., Holmes, T. H., Dekker, C. L., Kemble, G. W., Arvin, A. M., & Greenberg, H. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002975 · Cited by 227
Chiew Tong, N. K., Beran, J., Kee, S. A., Miguel, J. L., SanNchez, C., Bayas, J. M., Vilella, A., De Juanes, J. R., Arrazola, P., Calbo-Torrecillas, F., et al. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00689.x · Cited by 219
A Compendium of Vaccine Adjuvants and Excipients
Vogel, F. R., & Powell, M. F. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_7 · Cited by 217
Seubert, A., Calabro, S., Santini, L., Galli, B., Genovese, A., Valentini, S., Aprea, S., Colaprico, A., D'Oro, U., Giuliani, M. M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107941108 · Cited by 191
Self-citationEnhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., O'Hagan, D. T., & Podda, A. (2009) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819d6394 · Cited by 190
Self-citationSafety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
De Donato, S., Granoff, D., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., Senatore, F., Verweij, P., Fritzell, B., & Podda, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00138-3 · Cited by 184
(2004) · CRC Press eBooks · doi:10.1201/9781439834404 · Cited by 181
Effectiveness of Adjuvanted Influenza Vaccination in Elderly Subjects in Northern Italy
Mannino, S., Villa, M., Apolone, G., Weiss, N. S., Groth, N., Aquino, I., Boldori, L., Caramaschi, F., Gattinoni, A., Malchiodi, G., et al. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kws313 · Cited by 171
Straus, S. E., Wald, A., Kost, R. G., McKenzie, R., Langenberg, A. G. M., Hohman, P., Lekstrom, J., Cox, E., Nakamura, M., Sekulovich, R., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514103 · Cited by 169
Audran, R., Cachat, M., Lurati, F., Soé, S., Leroy, O. Y., Corradin, G., Druilhe, P., & Spertini, F. (2005) · Infection and Immunity · doi:10.1128/iai.73.12.8017-8026.2005 · Cited by 153
MF59 adjuvant: the best insurance against influenza strain diversity
O’Hagan, D. T., Rappuoli, R., Gregorio, E. D., Tsai, T. F., & Giudice, G. D. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.23 · Cited by 149
Self-citationSafety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations
Atmar, R. L., Keitel, W., Patel, S. M., Katz, J. M., She, D., Sahly, H. M. E., Pompey, J. M., Cate, T. R., & Couch, R. B. (2006) · Clinical Infectious Diseases · doi:10.1086/508174 · Cited by 148
Ott, G., Barchfeld, G. L., & Nest, G. V. (1995) · Vaccine · doi:10.1016/0264-410x(95)00089-j · Cited by 147
Self-citationPasternak, B., Svanström, H., Mølgaard‐Nielsen, D., Krause, T. G., Emborg, H., Melbye, M., & Hviid, A. P. (2012) · JAMA · doi:10.1001/jama.2012.6131 · Cited by 136
Ansaldi, F., Bacilieri, S., Durando, P., Sticchi, L., Valle, L., Montomoli, E., Icardi, G., Gasparini, R., & Crovari, P. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.01.019 · Cited by 134
Banzhoff, A., Nacci, P., & Podda, A. (2003) · Gerontology · doi:10.1159/000069172 · Cited by 129
GIUDICE, G., Hilbert, A., Bugarini, R., Minutello, A., POPOVA, O., Toneatto, D., Schöndorf, I., Borkowski, A., Rappuoli, R., & Podda, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.015 · Cited by 119
Self-citationSafety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study
Heikkinen, T., Young, J., van Beek, E., Franke, H. R., Verstraeten, T., Weil, J., & Cioppa, G. D. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.07.007 · Cited by 104
Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., Nest, G. A. V., & Hsu, H. H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00088-2 · Cited by 103
Self-citationTraquina, P., Morandi, M., Contorni, M., & Nest, G. V. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.6.1168 · Cited by 100
Self-citationPuig‐Barberà, J., Díez‐Domingo, J., Belenguer‐Varea, Á., Chavarri, G. S., Rodrigo, J. A. L., Pérez‐Hoyos, S., & Vidal, D. G. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.08.039 · Cited by 98
Ansaldi, F., Zancolli, M., Durando, P., Montomoli, E., Sticchi, L., Del Giudice, G., & Icardi, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.030 · Cited by 96
Antibodies to Squalene in Gulf War Syndrome
Asa, P. B., Cao, Y., & Garry, R. F. (2000) · Experimental and Molecular Pathology · doi:10.1006/exmp.1999.2295 · Cited by 96
Tsai, T. F., Crucitti, A., Nacci, P., Nicolay, U., Cioppa, G. D., Ferguson, J., & Clemens, R. L. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.580777 · Cited by 93
Elkayam, O., Sharon, A., Mendelson, E., Schwaber, M. J., Grotto, I., Wollman, J., Arad, U., Brill, A., Paran, D., Levartovsky, D., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20465 · Cited by 91
MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)
Baudner, B. C., Ronconi, V., Casini, D., Tortoli, M., Kazzaz, J., Singh, M., Hawkins, L. D., Wack, A., & O’Hagan, D. T. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9859-5 · Cited by 87
Self-citationThe Adjuvant MF59: A 10-Year Perspective
Ott, G. S., Radhakrishnan, R., Fang, J.-H., & Hora, M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-083-7:211 · Cited by 82
Self-citationPuig‐Barberà, J., Díez‐Domingo, J., Pérez‐Hoyos, S., Belenguer‐Varea, Á., & Vidal, D. G. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.017 · Cited by 79
Rahier, J. F., Papay, P., Salleron, J., Sebastian, S., Marzo, M., Peyrin‐Biroulet, L., García-Sánchez, V., Fries, W., van Asseldonk, D. P., Farkas, K., et al. (2011) · Gut · doi:10.1136/gut.2010.233981 · Cited by 79
Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene
Giudice, G. D., Fragapane, E., Bugarini, R., Hora, M., Henriksson, T., Palla, E., O’Hagan, D. T., Donnelly, J., Rappuoli, R., & Podda, A. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00191-06 · Cited by 78
Self-citationBernstein, D. I., Schleiss, M. R., Berencsi, K., Gönczöl, É., Dickey, M., Khoury, P., Cadoz, M., Méric, C., Zahradnik, J. M., Duliège, A., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/339003 · Cited by 77
Iob, A., Brianti, G., Zamparo, E., & Gallo, T. (2005) · Epidemiology and Infection · doi:10.1017/s0950268805003936 · Cited by 77
MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice
Higgins, D. A., Carlson, J. R., & Nest, G. V. (1996) · Vaccine · doi:10.1016/0264-410x(95)00240-2 · Cited by 74
Self-citationKeitel, W. A., Groth, N., Lattanzi, M., Praus, M., Hilbert, A. K., Borkowski, A., & Tsai, T. F. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.019 · Cited by 73
Otten, G. R., Schaefer, M. E., Doe, B., Liu, H., Srivastava, I. K., Megede, J. Z., Kazzaz, J., Lian, Y., Singh, M., Ugozzoli, M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8189-8200.2005 · Cited by 72
Self-citationMasihi, K. N., Lange, W., Brehmer, W., & Ribi, E. E. (1986) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(86)90116-5 · Cited by 71
Safety and Immunogenicity of a Genetically Engineered Human Immunodeficiency Virus Vaccine
Wintsch, J., Chaignat, C., Braun, D. G., Jeannet, M., Stalder, H., Abrignani, S., Montagna, D., Clavijo, F., Moret, P., Dayer, J.-M., et al. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.2.219 · Cited by 68
Herpes simplex viruses: is a vaccine tenable?
Whitley, R. J., & Roizman, B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16126 · Cited by 68
Gulf War and Health: Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines
Ce, F., Ct, L., & Sox, H. C. (2000) · Cited by 65
Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age
Arguedas, A. G., Soley, C., & LINDERT, K. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0909988 · Cited by 62
Zuccotti, G., Pogliani, L., Pariani, E., Amendola, A., & Zanetti, A. R. (2010) · JAMA · doi:10.1001/jama.2010.1729 · Cited by 62
Direction of Research on Vaccination against Influenza—New Studies with Immunologic Adjuvants
SALK, J. E., Laurent, A. M., & Bailey, M. L. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.6.669 · Cited by 55
Cataldo, D. M., & Nest, G. V. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00115-1 · Cited by 54
Self-citationExposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis
Tsai, T. F., Kyaw, M. H., Novicki, D. L., Nacci, P., Rai, S., & Clemens, R. L. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.11.077 · Cited by 54
Real-time monitoring of the influenza vaccine field effectiveness
Legrand, J., Vergu, E., & Flahault, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.063 · Cited by 54
Camilloni, B., Neri, M., Lepri, E., & Iorio, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.078 · Cited by 52
Cheong, H. J., Song, J. Y., Heo, J. Y., Noh, J. Y., Choi, W. S., Park, D. W., Wie, S., & Kim, W. J. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05111-11 · Cited by 52
Banzhoff, A., Haertel, S., & Praus, M. (2011) · Human Vaccines · doi:10.4161/hv.7.5.14821 · Cited by 50
An alternative renewable source of squalene for use in emulsion adjuvants
Brito, L. A., Chan, M., Baudner, B. C., Gallorini, S., Santos, G., O’Hagan, D. T., & Singh, M. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.067 · Cited by 43
Self-citationMeier, S., Bel, M., L’Huillier, A. G., Crisinel, P. A., Combescure, C., Kaiser, L., Grillet, S., Posfay-Barbe, K. M., & Siegrist, C. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.02.094 · Cited by 40
Kajaste‐Rudnitski, A., Galli, L., Nozza, S., Tambussi, G., Pietro, A. D., Pellicciotta, G., Monti, A., Mascagni, P., Moro, M., & Vicenzi, E. (2010) · AIDS · doi:10.1097/qad.0b013e328341afa8 · Cited by 38
Cioppa, G. D., Nicolay, U., LINDERT, K. A., Leroux-Roels, G. G., Clément, F., Castellino, F., Galli, G., Groth, N., & Giudice, G. D. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.18445 · Cited by 37
Self-citationHuang, W., Chen, W., Teng, H., Huang, W.-I., Huang, Y.-W., Hsu, C.-W., & Chuang, J.-H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023049 · Cited by 34
DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques
Cherpelis, S., Jin, X., Gettie, A., Ho, D. D., Barnett, S. W., Shrivastava, I., & Stamatatos, L. (2001) · Immunology Letters · doi:10.1016/s0165-2478(01)00265-6 · Cited by 33
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients
Fabbiani, M., Giambenedetto, S. D., Sali, M., Farina, S., Sansonetti, P., Tamburrini, E., Verme, L. Z. D., Delogu, G., Luca, A. D., Kelvin, D. J., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.02.020 · Cited by 33
Esposito, S., Tagliaferri, L., Daleno, C., Valzano, A. G., Picciolli, I., Tel, F., Prunotto, G., Serra, D., Galeone, C., Plebani, A., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.047 · Cited by 30
Nassim, C., Christensen, S., Henry, D. C., Holmes, S. J., Hohenboken, M. J., & Kanesa-thasan, N. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31824b9545 · Cited by 30
Faenzi, E., Zedda, L., Bardelli, M., Spensieri, F., Borgogni, E., Volpini, G., Buricchi, F., Pasini, F. L., Capecchi, P. L., Montanaro, F., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.020 · Cited by 28
Self-citationHatz, C., von Sonnenburg, F., Casula, D., Lattanzi, M., & Leroux-Roels, G. G. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.017 · Cited by 26
Block, S. L., Ruiz-Palacios, G. M., Guerrero, M. L., Beygo, J., Sales, V., & Holmes, S. J. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318257644f · Cited by 25
Response to influenza vaccine in people with non-protective HI antibody titers
Baldo, V., Baldovin, T., Floreani, A., Minuzzo, M., & Trivello, R. (2006) · European Journal of Epidemiology · doi:10.1007/s10654-006-9071-4 · Cited by 21
Palma, P., Romiti, M. L., Bernardi, S., Pontrelli, G., Mora, N., Santilli, V., Tchidjou, H. K., Aquilani, A., Cotugno, N., Alghisi, F., et al. (2012) · Biologicals · doi:10.1016/j.biologicals.2011.12.001 · Cited by 19
Kojimahara, N., Maeda, A., KASE, T., & Yamaguchi, N. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.009 · Cited by 19
Song, J. Y., Cheong, H. J., Seo, Y. B., Kim, I. S., Noh, J. Y., Heo, J. Y., Choi, W. S., Lee, J., & Kim, W. J. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00026-12 · Cited by 13
Baldo, V., & Baldovin, T. (2012) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000112 · Cited by 6
Cited by
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Self-citationVaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C.-J., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 885
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 699
Advances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 597
Metadata
- Authors
- O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2013-01
- Volume
- 12
- Issue
- 1
- Pages
- 13-30
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2156580403
- Cited by
- 313
- References
- 107
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.